Follicular Lymphoma Excellence Forum

Follicular Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Carla Casulo, MD, Talks About the Role of Observation in Treating FL

02/01/2021

Dr Casulo discusses the role that observation plays in the treatment of patients with FL.

Dr Casulo discusses the role...

02/01/2021

Oncology

Videos

Dr Evans Discusses Updates in the Treatment of Patients With FL

01/29/2021

In this video, Andrew Evens, DO, MSc, FACP, discusses a couple of key publications and data sets in the field of EZH2-mutated and EZH2 wild type FL.

In this video, Andrew Evens, DO,...

01/29/2021

Oncology

Videos

Peter Martin, MD, Discusses the Value of PET/CT Status in FL

01/08/2021

Peter Martin, MD, provides an overview of 2 clinical studies that explored the prognostic value and involvement of PET/CT status in patients with FL.

Peter Martin, MD, provides an...

01/08/2021

Oncology

Videos

Targeting EZH2 in the Context of Follicular Lymphoma

09/20/2020

Peter Martin, MD, discusses recent advancements in the treatment of patients with EZH2-positive FL.

Peter Martin, MD, discusses...

09/20/2020

Oncology

Videos

Obinutuzumab Plus Venetoclax Well-Tolerated in Previously Untreated FL

07/23/2020

Peter Martin, MD, discussed the findings and clinical significance of the SAKK 35/15 clinical trial.

Peter Martin, MD, discussed the...

07/23/2020

Oncology

Videos

Novel Allogeneic CAR-T Products Appear Safe in LBCL and FL

06/21/2020

Sattva Neelapu, MD, discusses early results from the ALPHA study suggesting that ALLO-501 and ALLO-647 are safe and may be effective in LBCL and FL.

Sattva Neelapu, MD, discusses...

06/21/2020

Oncology

Commentary

Challenges of Managing FL: A Focus on PI3K Inhibitors and Next-Line Therapy

04/26/2020

Elizabeth Brem, MD, discusses some of the challenges with managing FL, focusing on the incorporation of PIK3 kinase inhibitors in the treatment of these patients.

Elizabeth Brem, MD, discusses...

04/26/2020

Oncology

Videos

How I Practice Now: Treating FL During the Global Pandemic

04/23/2020

John Allan, MD, explains the impact the COVID-19 pandemic has had on the treatment of patients with follicular lymphoma and other indolent lymphomas.

John Allan, MD, explains the...

04/23/2020

Oncology

Videos

Ibrutinib Plus Rituximab Demonstrates Activity in Frontline FL

04/20/2020

Nathan Fowler, MD, discusses the results of of phase 2 study that evaluated the activity and safety of ibrutinib in combination with rituximab in untreated FL.

Nathan Fowler, MD, discusses the...

04/20/2020

Oncology

$What is the Best Treatment Approach for Patients With Relapsed/Refractory FL?$

Videos

What is the Best Treatment Approach for Patients With Relapsed/Refractory FL?

03/11/2020

Elizabeth Brem, MD, argues in favor of chemotherapy and or stem cell transplant-based regimens to treat relapsed/refractory FL.

Elizabeth Brem, MD, argues in...

03/11/2020

Oncology

Recent News

Commentary

Challenges of Managing FL: A Focus on PI3K Inhibitors and Next-Line Therapy

04/26/2020

Elizabeth Brem, MD, discusses some of the challenges with managing FL, focusing on the incorporation of PIK3 kinase inhibitors in the treatment of these patients.

Elizabeth Brem, MD, discusses...

04/26/2020

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology